Skip to main content

Table 1 Baseline patient demographics and clinical characteristics for the overall study population and by survivor status

From: Outcomes in elderly patients admitted to the intensive care unit with solid tumors

  Overall (n = 262) ICU survivors (n = 174) ICU non-survivors (n = 88) p value
Age (years) 75.2 ± 6.7 75.7 ± 6.8 74.3 ± 6.5 0.13
Male 162 (61.8) 101 (58.0) 61 (69.3) 0.08
Comorbidities
 Tobacco use 106 (40.5) 65 (37.4) 41 (46.6) 0.15
 Diabetes 57 (21.8) 35 (20.1) 22 (25) 0.36
 Chronic respiratory failure 33 (12.6) 23 (13.2) 10 (11.4) 0.18
 Chronic kidney failure 29 (11.1) 23 (13.2) 6 (6.8) 0.12
Primary tumor site 0.02
 Gastrointestinal 71 (27.1) 52 (29.9) 19 (21.6)  
 Lung 68 (26) 45 (25.9) 23 (26.1)  
 Genitourinary 60 (22.9) 43 (24.7) 17 (19.3)  
 Head and neck 31 (11.8) 11 (6.3) 20 (22.7)  
 Breast 18 (6.9) 13 (7.5) 5 (5.7)  
 Gynecological 9 (3.4) 7 (4) 2 (2.3)  
 Sarcoma 3 (1.1) 2 (1.2) 1 (1.1)  
 Unknown 2 (0.8) 1 (0.6) 1 (1.1)  
Metastasis
 Yes 158 (60.3) 110 (63.2) 48 (54.6) 0.17
 Other 66 (25.3) 42 (24.3) 24 (27.3) 0.58
 Lymph node 58 (22.2) 39 (22.5) 19 (21.6) 0.93
 Lung 57 (21.8) 41 (23.7) 16 (18.2) 0.32
 Bone 46 (17.6) 31 (17.9) 15 (17.1) 0.88
 Liver 38 (14.6) 26 (15) 12 (13.6) 0.78
 Brain 9 (3.5) 6 (3.5) 3 (3.4) 0.73
 Pulmonary lymphangitis 6 (2.3) 4 (2.3) 2 (2.3) 0.67
 Missing 1 (0.4) 1 (0.6) 0 (0)  
Anticancer treatment before ICU admission
 Number of previous systemic anti-tumoral treatments [median (IQR)] 1 (0;1) 1 (0;1) 1 (0;1) 0.32
 Missing 8 (3) 5 (2.9) 3 (3.4)  
 Chemotherapy 94 (56.3) 66 (60.6) 28 (48.3) 0.18
 Targeted therapy 31 (18.7) 22 (20.2) 9 (15.8)  
 Missing 95 (36.3) 65 (37.3) 30 (34)  
Performance status
 0 or 1 98 (46.4) 64 (45.7) 34 (47.9) 0.98
 2 86 (40.8) 58 (41.4) 28 (39.4)  
 3 or 4 27 (12.9) 18 (12.8) 9 (12.7)  
 Missing 51 (19.5) 34 (19.5) 17 (19.3)  
  1. Data are mean ± SD or number of patients (%)